Application of Physiologically Based Pharmacokinetic Modeling to the Understanding of Bosutinib Pharmacokinetics: Prediction of Drug–Drug and Drug–Disease Interactions

Bosutinib is an orally available Src/Abl tyrosine kinase inhibitor indicated for the treatment of patients with Philadelphia chromosome–positive chronic myelogenous leukemia. Bosutinib is predominantly metabolized by CYP3A4 as the primary clearance mechanism. The main objectives of this study were t...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Drug metabolism and disposition 2017-04, Vol.45 (4), p.390-398
Hauptverfasser:	Ono, Chiho, Hsyu, Poe-Hirr, Abbas, Richat, Loi, Cho-Ming, Yamazaki, Shinji
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Oral Aniline Compounds - administration & dosage Aniline Compounds - pharmacokinetics Area Under Curve Computer Simulation Cytochrome P-450 CYP3A - metabolism Cytochrome P-450 CYP3A Inducers - pharmacokinetics Cytochrome P-450 CYP3A Inhibitors - pharmacokinetics Drug Interactions Humans Ketoconazole - pharmacokinetics Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy Models, Biological Nitriles - administration & dosage Nitriles - pharmacokinetics Protein Kinase Inhibitors - administration & dosage Protein Kinase Inhibitors - pharmacokinetics Proto-Oncogene Proteins c-abl - antagonists & inhibitors Quinolines - administration & dosage Quinolines - pharmacokinetics Rifampin - pharmacokinetics src-Family Kinases - antagonists & inhibitors Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!